Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (2016 - 2025)

Tg Therapeutics has reported Shares Outstanding over the past 10 years, most recently at $158.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $158.8 million for Q4 2025, up 1.69% from a year ago — trailing twelve months through Dec 2025 was $158.8 million (up 1.69% YoY), and the annual figure for FY2025 was $158.8 million, up 1.69%.
  • Shares Outstanding for Q4 2025 was $158.8 million at Tg Therapeutics, up from $155.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for TGTX hit a ceiling of $158.8 million in Q4 2025 and a floor of $41309.0 in Q1 2023.
  • Median Shares Outstanding over the past 5 years was $151.2 million (2023), compared with a mean of $143.0 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 99.97% in 2023 and later skyrocketed 377325.99% in 2024.
  • Tg Therapeutics' Shares Outstanding stood at $41309.0 in 2021, then skyrocketed by 354366.82% to $146.4 million in 2022, then grew by 3.44% to $151.5 million in 2023, then increased by 3.13% to $156.2 million in 2024, then increased by 1.69% to $158.8 million in 2025.
  • The last three reported values for Shares Outstanding were $158.8 million (Q4 2025), $158.8 million (Q3 2025), and $158.8 million (Q2 2025) per Business Quant data.